Clinical trials
Heart Transplant Infection clinical trials
Below are recruiting heart transplant infection clinical trials, each written for real people, not researchers. We’re tracking 48 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07758894Recruiting
Breathing without a breathing tube during heart transplant surgery
This study tests whether heart transplant surgery can be done while the patient is awake and breathing on their own, instead of using a breathing tube. If successful, it may lead to faster recovery and fewer complications.
Guangzhou, GuangdongAges 18 years+ - NCT06341543Recruiting
CMV blood test to guide treatment after organ transplant
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
Grenoble, MarylandAges 18 years+ - NCT06464016Recruiting
Infections in Kids With Berlin Heart Pumps
This study looks at infections in children who used a Berlin Heart mechanical heart pump. It aims to find better ways to prevent and treat these infections.
LyonAges 1 day–18 years - NCT07195032RecruitingPhase 4
MMR vaccine safety in kids after heart transplant
This trial tests whether the MMR (measles, mumps, rubella) vaccine is safe and works well for children who have had a heart transplant. It may help protect you from these diseases if you haven't had the vaccine or no longer have immunity.
Kansas City, MissouriAges 1–17 - NCT07079735RecruitingPhase 2/Phase 3
Preventing CMV after heart transplant
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
New York, New YorkAges 18–99 - NCT06986980Recruiting
Gut Infection After Heart Transplant Study
This study looks at a rare gut infection (microsporidiosis) in people who have had a heart transplant. If you had this infection before 2025 and the diagnosis was made in France, your medical records may be reviewed to learn more about the infection.
Clermont-FerrandAges Any age - NCT06659952Recruiting
HIV+ donor hearts for HIV+ recipients
This trial tests whether hearts from donors who had HIV can be safely transplanted into people with HIV who need a heart transplant. It may offer a new option for those on the waiting list.
Dallas, TexasAges 18 years+ - NCT06478017RecruitingPhase 2
Belatacept for heart transplant recipients
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
Los Angeles, CaliforniaAges 18–76 - NCT06428097RecruitingPhase 1
Thyroid hormone before heart transplant
This study tests whether giving a thyroid hormone supplement called levothyroxine before a heart transplant can help with recovery. It is for people already listed for a heart transplant who do not have thyroid problems.
San Francisco, CaliforniaAges 18 years+ - NCT04477629RecruitingPhase 2
Belatacept for first-time heart transplant recipients
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
New York, New YorkAges 18–75 - NCT06346665Recruiting
Transplant infection study for organ and stem cell recipients
This trial follows people who have had a recent organ or stem cell transplant to learn more about infections and how they can be prevented. You may be asked to provide samples and information over time.
MünchenAges Any age - NCT06625073RecruitingPhase 4
SGLT2i for heart transplant recipients
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
Palo Alto, CaliforniaAges 18 years+ - NCT05729009Recruiting
Testing blood-vessel function changes after heart transplant
This study looks at how tiny blood vessels in the body work over time in people who have had a heart transplant. It aims to better understand changes in blood flow and how these may relate to health after transplant.
Rio de JaneiroAges 18–75 - NCT04924491RecruitingPhase 1/Phase 2
Treg cell therapy to help prevent rejection after child heart transplant
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
Madrid, MadridAges Up to 2 years - NCT05947071RecruitingPhase 2
Higher-dose flu vaccine versus standard dose in child transplant patients
This trial compares a higher-dose flu vaccine to the standard dose in children who recently received a kidney, heart, and/or liver transplant. It aims to see which dose better protects children against influenza while checking for safety.
Stanford, CaliforniaAges 3–17 - NCT05626530RecruitingPhase 4
Letermovir to prevent CMV after transplant illness
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
Boston, MassachusettsAges 18–75 - NCT06387446Recruiting
Donated heart valve transplant for children and young adults
This study is testing a new way to replace a damaged heart valve using a donated valve (allograft) that may last longer and work better for children and young adults. It may be a good option if you need a new valve and have few other choices.
Boston, MassachusettsAges 4 weeks–50 years - NCT03292861Enrolling by invitationPhase 2
Thymoglobulin after first heart transplant: safety and effect
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
Los Angeles, CaliforniaAges 18–70 - NCT04180085RecruitingPhase 2
Belatacept to protect kidneys in heart transplant patients
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
BordeauxAges 18 years+ - NCT07235683RecruitingPhase 4
Stronger CMV treatment for lung transplant recipients
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Toronto, OntarioAges 18 years+ - NCT07009548Enrolling by invitationPhase 4
CytoGam for CMV in solid organ transplant recipients
This trial tests whether adding CytoGam (an antibody treatment) to standard antiviral therapy can better treat CMV (a common virus) in people who have received a solid organ transplant. It may help those with high virus levels or a new infection after transplant.
Pittsburgh, PennsylvaniaAges 18–75 - NCT05597540RecruitingPhase 3
Shorter antibiotics for kidney transplant kidney infections
This study compares giving antibiotics for 7 days versus 14 days to treat acute kidney infections (pyelonephritis) in people with kidney transplants. It aims to see if the shorter course works just as well and is safer or easier to complete.
BordeauxAges 18 years+ - NCT06939751Recruiting
Testing microRNA levels to personalize heart transplant care
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
Los Angeles, CaliforniaAges 18–99 - NCT06532890Recruiting
Using microRNAs to personalize heart transplant medicines in children
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Aurora, ColoradoAges Up to 18 years
Hear when a new Heart Transplant Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for heart transplant infection?
- Yes. Clin2 currently lists 48 recruiting heart transplant infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a heart transplant infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a heart transplant infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.